Literatur
- 1 World Health Organization .The facts about smoking and health. 2006
- 2 Becker N, Wahrendorf J H. Krebsatlas der Bundesrepublik Deutschland 1981 – 1990. Heidelberg:
Springer 1998
- 3 Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (GKID) .Krebs
in Deutschland. Häufigkeiten und Trends. Saarbrücken: Krebsregister 2006
- 4 Deutsches Krebsforschungszentrum (DKFZ) .Passivrauchende Kinder in Deutschland –
Frühe Schädigungen für ein ganzes Leben. Heidelberg 2003
- 5 US Department of Health and Human Services .The health benefits of smoking cessation:
A report of the Surgeon General. Atlanta: US Department of Health and Human Services,
Centers for Disease Control and Prevention, Center for Chronic Disease Prevention
and Health Promotion, Public Health Service, Office on Smoking and Health 1990
- 6
Balfour D J, Fagerstrom K O.
Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative
disorders.
Pharmacol Ther.
1996;
72
51-81
- 7
Balfour D J, Benwell M E, Birrell C E. et al .
Sensitization of the mesoaccumbens dopamine response to nicotine.
Pharmacol Biochem Behav.
1998;
59
1021-1030
- 8
Pomerleau O F.
Nicotine and the central nervous system: biobehavioral effects of cigarette smoking.
Am J Med.
1992;
93
2S-7S
- 9
Epping-Jordan M P, Watkins S S, Koob G F. et al .
Dramatic decreases in brain reward function during nicotine withdrawal.
Nature.
1998;
393
76-79
- 10
Picciotto M R, Zoli M, Rimondini R. et al .
Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing
properties of nicotine.
Nature.
1998;
391
173-177
- 11
Furtado R.
Implicações anestésicas do tabagismo.
Rev Bras Anestesiol.
2002;
52
354-367
- 12 Batra A. Tabakabhängigkeit. Biologische und psychosoziale Entstehungsbedingungen
und Therapiemöglichkeiten. Darmstadt: Steinkopf 2000
- 13
Marques A CPR. et al .
Consenso sobre o tratamento da dependência de nicotina.
Rev Bras Psiquiatr.
2001;
23
200-214
- 14 US Department of Health and Human Services .The Health Consequences of Smoking:
Nicotine Addiction: A Report of the Surgeon General. Rockville, Maryland 1988
- 15 Dilling H, Monbour W, Schmidt M H. Internationale Klassifikation psychischer Störungen:
ICD-10, Kapitel V (F). Göttingen: Huber 1991
- 16 Saß H, Wittchen H U, Zaudig M. Diagnostisches und Statistisches Manual Psychischer
Störungen DSM IV. Göttingen, Bern, Toronto, Seattle: Hogrefe 1996
- 17
Batra A, Fagerström K O.
Neue Aspekte der Nikotinabhängigkeit und Raucherentwöhnung.
Sucht.
1997;
43
277-282
- 18
Breslau N, Johnson E O, Hiripi E. et al .
Nicotine dependence in the United States: prevalence, trends, and smoking persistence.
Arch Gen Psychiatry.
2001;
58
810-816
- 19 World Health Organization .Tobacco or health: a global status report. Geneva: World
Health Organization 1997
- 20
Fagerstrom K O, Schneider N G.
Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire.
J Behav Med.
1989;
12
159-182
- 21
Lagrue G, Lafnoune N, Cormier S. et al .
Urinary cotinine-creatinine ratio as a marker of nicotine intake: a guide for the
nicotine replacement therapy during smoking cessation. Congrès annuel ERS, Florence
1993.
Eur Respir J.
1993;
6
- 22 Fiore M C, Bailey W C, Cohen S J. Treating tobacco use and dependence. Clinical
practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public
Health Service 2000
- 23
Haustein K O.
Pharmacotherapy of nicotine dependence.
Int J Clin Pharmacol Ther.
2000;
38
273-290
- 24
Henningfield J E.
Nicotine medications for smoking cessation.
N Engl J Med.
1995;
333
1196-1203
- 25
Mühling S, Nowak D.
9 Thesen zur Raucherentwöhnung.
Suchtmed.
2004;
6
- 26
Nowak D, Hoch E.
Raucherentwöhnung – Pharmakologie, Effizienz und Hemmnisse.
Bay Int.
2005;
25
118-126
- 27
Schön S, Nowak D.
Medikamentöse Verfahren zur Raucherentwöhnung.
Suchtmed.
2002;
4
189-199
- 28
Silagy C, Lancaster T, Stead L. et al .
Nicotine replacement therapy for smoking cessation.
Cochrane Database Syst Rev.
2004;
CD000146
- 29
Henningfield J E, Fant R V, Buchhalter A R. et al .
Pharmacotherapy for nicotine dependence.
CA Cancer J Clin.
2005;
55
281-299; quiz 322 – 283, 325
- 30
Mitrouska I, Bouloukaki I, Siafakas N M.
Pharmacological approaches to smoking cessation.
Pulm Pharmacol Ther.
2007;
20
220-232
- 31
Wu P, Wilson K, Dimoulas P. et al .
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.
BMC Public Health.
2006;
6
300
- 32
Fiore M C.
Treating tobacco use and dependence: an introduction to the US Public Health Service
Clinical Practice Guideline.
Respir Care.
2000;
45
1196-1199
- 33
Hjalmarson A, Franzon M, Westin A. et al .
Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled,
double-blind study.
Arch Intern Med.
1994;
154
2567-2572
- 34
Sutherland G, Stapleton J A, Russell M A. et al .
Randomised controlled trial of nasal nicotine spray in smoking cessation.
Lancet.
1992;
340
324-329
- 35
Sutherland G, Russell M A, Stapleton J. et al .
Nasal nicotine spray: a rapid nicotine delivery system.
Psychopharmacology (Berl).
1992;
108
512-518
- 36
Choi J H, Dresler C M, Norton M R. et al .
Pharmacokinetics of a nicotine polacrilex lozenge.
Nicotine Tob Res.
2003;
5
635-644
- 37
Shiffman S, Dresler C M, Hajek P. et al .
Efficacy of a nicotine lozenge for smoking cessation.
Arch Intern Med.
2002;
162
1267-1276
- 38
Blondal T, Gudmundsson L J, Olafsdottir I. et al .
Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with
six year follow up.
Bmj.
1999;
318
285-288
- 39
Bohadana A, Nilsson F, Rasmussen T. et al .
Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation:
a randomized, double-blind, placebo-controlled trial.
Arch Intern Med.
2000;
160
3128-3134
- 40
Kornitzer M, Boutsen M, Dramaix M. et al .
Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled
clinical trial.
Prev Med.
1995;
24
41-47
- 41
Benowitz N L.
Clinical pharmacology of nicotine: implications for understanding, preventing, and
treating tobacco addiction.
Clin Pharmacol Ther.
2008;
83
531-541
- 42
Hays J T, Ebbert J O.
Bupropion for the treatment of tobacco dependence: guidelines for balancing risks
and benefits.
CNS Drugs.
2003;
17
71-83
- 43
Slemmer J E, Martin B R, Damaj M I.
Bupropion is a nicotinic antagonist.
J Pharmacol Exp Ther.
2000;
295
321-327
- 44
Hurt R D, Sachs D P, Glover E D. et al .
A comparison of sustained-release bupropion and placebo for smoking cessation.
N Engl J Med.
1997;
337
1195-1202
- 45
Lee A M, Jepson C, Hoffmann E. et al .
CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
Biol Psychiatry.
2007;
62
635-641
- 46
Jorenby D E, Leischow S J, Nides M A. et al .
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking
cessation.
N Engl J Med.
1999;
340
685-691
- 47
Hughes J R, Stead L F, Lancaster T.
Antidepressants for smoking cessation.
Cochrane Database Syst Rev.
2007;
CD000031
- 48
Roddy E.
Bupropion and other non-nicotine pharmacotherapies.
Bmj.
2004;
328
509-511
- 49
George T P, O'Malley S S.
Current pharmacological treatments for nicotine dependence.
Trends Pharmacol Sci.
2004;
25
42-48
- 50
Jorenby D.
Clinical efficacy of bupropion in the management of smoking cessation.
Drugs.
2002;
62 Suppl 2
5-35
- 51
Aubin H J.
Tolerability and safety of sustained-release bupropion in the management of smoking
cessation.
Drugs.
2002;
62 Suppl 2
45-52
- 52
Settle Jr E C.
Bupropion sustained release: side effect profile.
J Clin Psychiatry.
1998;
59 Suppl 4
32-36
- 53
da Costa C L, Younes R N, Lourenco M T.
Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline
to placebo.
Chest.
2002;
122
403-408
- 54
Hall S M, Reus V I, Munoz R F. et al .
Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.
Arch Gen Psychiatry.
1998;
55
683-690
- 55
Ferry L H.
Non-nicotine pharmacotherapy for smoking cessation.
Prim Care.
1999;
26
653-669
- 56
Abbot N C, Stead L F, White A R. et al .
Hypnotherapy for smoking cessation.
Cochrane Database Syst Rev.
2000;
CD001008
- 57
Prochazka A V, Kick S, Steinbrunn C. et al .
A randomized trial of nortriptyline combined with transdermal nicotine for smoking
cessation.
Arch Intern Med.
2004;
164
2229-2233
- 58
Gourlay S G, Stead L F, Benowitz N L.
Clonidine for smoking cessation.
Cochrane Database Syst Rev.
2004;
CD000058
- 59
Jorenby D E, Hays J T, Rigotti N A. et al .
Efficacy of varenicline, an alpha-4-beta-2-nicotinic acetylcholine receptor partial
agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized
controlled trial.
Jama.
2006;
296
56-63
- 60
Cohen C, Perrault G, Voltz C. et al .
SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational
and dopamine-releasing effects of nicotine in rats.
Behav Pharmacol.
2002;
13
451-463
- 61 Anthenelli R, Despres J. Effects of rimonabant in the reduction of major car-diovascular
risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated
to quit). Presented at Am. College Cardiol. 53rd Annu. Sci. Session. New Orleans,
LA: Rapid News Summaries 2004
- 62 Anthenelli R. Rimonabantin smoking abstinence: the STRATUS-programm. in Proc. 11
Annu. Meet. Soc. Res. Nicotine Tobacco. Prague, Czech 2005
- 63 EMEA .Questions and answers on the safety of Acomplia (Rimonabant).
http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/H-666-qa.pdf. London: European
Medicines Agency 2007
- 64
Cerny T.
Anti-nicotine vaccination: where are we?.
Recent Results Cancer Res.
2005;
166
167-175
- 65
Hieda Y, Keyler D E, Ennifar S. et al .
Vaccination against nicotine during continued nicotine administration in rats: immunogenicity
of the vaccine and effects on nicotine distribution to brain.
Int J Immunopharmacol.
2000;
22
809-819
- 66
Pentel P R, Malin D H, Ennifar S. et al .
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates
its behavioral and cardiovascular effects in rats.
Pharmacol Biochem Behav.
2000;
65
191-198
- 67
Le Houezec J.
Why a nicotine vaccine?.
Clin Pharmacol Ther.
2005;
78
453-455
- 68
LeSage M G, Keyler D E, Pentel P R.
Current status of immunologic approaches to treating tobacco dependence: vaccines
and nicotine-specific antibodies.
Aaps J.
2006;
8
E65-75
- 69
Lindblom N, de Villiers S H, Kalayanov G. et al .
Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior
in rats.
Respiration.
2002;
69
254-260
- 70 Cytos Biotechnology .Impfstoff zur Behandlung der Nikotinsucht fördert anhaltende
Abstinenz während 12 Monaten bei Probanden mit hohen Antikörperwerten.
http://www.cytos.com/doc/Cytos_Press_D_051 117.pdf. Schlieren: Cytos Biotechnology
AG 2005
- 71
Hatsukami D K, Rennard S, Jorenby D. et al .
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
Clin Pharmacol Ther.
2005;
78
456-467
- 72
Maurer P, Jennings G T, Willers J. et al .
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety
and immunogenicity.
Eur J Immunol.
2005;
35
2031-2040
- 73
White A R, Rampes H, Campbell J L.
Acupuncture and related interventions for smoking cessation.
Cochrane Database Syst Rev.
2006;
CD000009
- 74
Balbani A, Montovani J.
Methods for smoking cessation and treatment of nicotine dependence.
Rev Bras Otorrinolaringol.
2005;
71
820-827
- 75
Villano L M, White A R.
Alternative therapies for tobacco dependence.
Med Clin North Am.
2004;
88
1607-1621
- 76
Stead L F, Lancaster T.
Group behaviour therapy programmes for smoking cessation.
Cochrane Database Syst Rev.
2002;
CD001007
- 77
West R, McNeill A, Raw M.
Smoking cessation guidelines for health professionals: an update. Health Education
Authority.
Thorax.
2000;
55
987-999
- 78 Deutsche Hauptstelle gegen die Suchtgefahren e. V. (DHS) .Frau SUCHT Gesundheit.
Die Luft anhalten oder: Warum rauchen Frauen?.
http://www.dhs.de/makeit/cms/cms_upload/dhs/die_luft_anhalten_low.pdf
Hamm 2000
Dipl. Psych. Bianca Kusma
Institut für Arbeitsmedizin
Thielallee 69 – 73
14159 Berlin
Email: bianca.kusma@charite.de
